Datavault AI (NASDAQ: DVLT) announced an expansion of its definitive licensing agreement with DataMeds AI Inc., extending the use of its PharmacyChain blockchain technology beyond pharmaceutical distribution into commercial healthcare, healthspan, and wellness applications. The amended agreement, announced on July 30, 2026, aims to support patient-controlled health data access, monetization, and real-world asset tokenization across pharmacy, medical, laboratory, and wearable device environments.
The expanded relationship leverages a behavioral healthcare patent portfolio focused on medical logistics, IoT population health, and AI-driven remote patient monitoring. Under the terms of the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS' outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes.
The companies stated that the agreement accelerates the deployment of Datavault AI's technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models. This move positions Datavault AI to capitalize on the growing demand for patient-centric health data management and tokenization.
Datavault AI's technology suite includes its Acoustic Sciences division, featuring WiSA, ADIO, and Sumerian patented technologies for spatial and multichannel wireless high-definition sound transmission, and its Data Science division, which leverages Web 3.0 and high-performance computing for data perception, valuation, and secure monetization. The company's platform serves multiple industries, including healthcare, through its Information Data Exchange, which enables Digital Twins and the licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata.
The global health and wellness market presents significant opportunities for Datavault AI and DataMEDS as they collaborate on new models for patient-controlled health data. The full press release is available at https://ibn.fm/vBAxH. More information about Datavault AI can be found at https://dvlt.ai.
This expansion marks a strategic move for Datavault AI as it extends its technology into commercial healthcare, potentially impacting how patients control and monetize their health data. The partnership could set a precedent for blockchain applications in healthcare data management, offering new revenue streams and enhanced patient autonomy.
